Characterization of hepcidin response to holotransferrin in novel recombinant TfR1 HepG2 cells

Kosha Mehta, Mark Busbridge, Derek Renshaw, Robert W Evans, Sebastien Farnaud, Vinood B Patel

    Research output: Contribution to journalArticle

    1 Citation (Scopus)
    23 Downloads (Pure)

    Abstract

    Hepcidin is the key regulator of systemic iron homeostasis. The iron-sensing mechanisms and the role of intracellular iron in modulating hepatic hepcidin secretion are unclear. Therefore, we created a novel cell line, recombinant-TfR1 HepG2, expressing iron-response-element-independent TFRC mRNA to promote cellular iron-overload and examined the effect of excess holotransferrin (5g/L) on cell-surface TfR1, iron content, hepcidin secretion and mRNA expressions of TFRC, HAMP, SLC40A1, HFE and TFR2. Results showed that the recombinant cells exceeded levels of cell-surface TfR1 in wild-type cells under basal (2.8-fold; p<0.03) and holotransferrin-supplemented conditions for 24h and 48h (4.4- and 7.5-fold, respectively; p<0.01). Also, these cells showed higher intracellular iron content than wild-type cells under basal (3-fold; p<0.03) and holotransferrin-supplemented conditions (6.6-fold at 4h; p<0.01). However, hepcidin secretion was not higher than wild-type cells. Moreover, holotransferrin treatment to recombinant cells did not elevate HAMP responses compared to untreated or wild-type cells. In conclusion, increased intracellular iron content in recombinant cells did not increase hepcidin responses compared to wild-type cells, resembling hemochromatosis. Furthermore, TFR2 expression altered within 4h of treatment, while HFE expression altered later at 24h and 48h, suggesting that TFR2 may function prior to HFE in HAMP regulation.

    Original languageEnglish
    Pages (from-to)37-45
    Number of pages9
    JournalBlood Cells, Molecules, and Diseases
    Volume61
    Early online date30 Jun 2016
    DOIs
    Publication statusPublished - Oct 2016

    Fingerprint

    Hepcidins
    Hep G2 Cells
    Iron
    holotransferrin
    Messenger RNA
    Iron Overload
    Hemochromatosis
    Response Elements
    Homeostasis

    Keywords

    • Hepcidin
    • Iron
    • HepG2
    • Hepatocyte
    • Transferrin

    Cite this

    Characterization of hepcidin response to holotransferrin in novel recombinant TfR1 HepG2 cells. / Mehta, Kosha; Busbridge, Mark; Renshaw, Derek; Evans, Robert W; Farnaud, Sebastien; Patel, Vinood B.

    In: Blood Cells, Molecules, and Diseases, Vol. 61, 10.2016, p. 37-45.

    Research output: Contribution to journalArticle

    @article{3aa086044e26453fadada91db8aebf59,
    title = "Characterization of hepcidin response to holotransferrin in novel recombinant TfR1 HepG2 cells",
    abstract = "Hepcidin is the key regulator of systemic iron homeostasis. The iron-sensing mechanisms and the role of intracellular iron in modulating hepatic hepcidin secretion are unclear. Therefore, we created a novel cell line, recombinant-TfR1 HepG2, expressing iron-response-element-independent TFRC mRNA to promote cellular iron-overload and examined the effect of excess holotransferrin (5g/L) on cell-surface TfR1, iron content, hepcidin secretion and mRNA expressions of TFRC, HAMP, SLC40A1, HFE and TFR2. Results showed that the recombinant cells exceeded levels of cell-surface TfR1 in wild-type cells under basal (2.8-fold; p<0.03) and holotransferrin-supplemented conditions for 24h and 48h (4.4- and 7.5-fold, respectively; p<0.01). Also, these cells showed higher intracellular iron content than wild-type cells under basal (3-fold; p<0.03) and holotransferrin-supplemented conditions (6.6-fold at 4h; p<0.01). However, hepcidin secretion was not higher than wild-type cells. Moreover, holotransferrin treatment to recombinant cells did not elevate HAMP responses compared to untreated or wild-type cells. In conclusion, increased intracellular iron content in recombinant cells did not increase hepcidin responses compared to wild-type cells, resembling hemochromatosis. Furthermore, TFR2 expression altered within 4h of treatment, while HFE expression altered later at 24h and 48h, suggesting that TFR2 may function prior to HFE in HAMP regulation.",
    keywords = "Hepcidin, Iron, HepG2, Hepatocyte, Transferrin",
    author = "Kosha Mehta and Mark Busbridge and Derek Renshaw and Evans, {Robert W} and Sebastien Farnaud and Patel, {Vinood B}",
    year = "2016",
    month = "10",
    doi = "10.1016/j.bcmd.2016.06.008",
    language = "English",
    volume = "61",
    pages = "37--45",
    journal = "Blood Cells, Molecules, and Diseases",
    issn = "1079-9796",
    publisher = "Elsevier",

    }

    TY - JOUR

    T1 - Characterization of hepcidin response to holotransferrin in novel recombinant TfR1 HepG2 cells

    AU - Mehta, Kosha

    AU - Busbridge, Mark

    AU - Renshaw, Derek

    AU - Evans, Robert W

    AU - Farnaud, Sebastien

    AU - Patel, Vinood B

    PY - 2016/10

    Y1 - 2016/10

    N2 - Hepcidin is the key regulator of systemic iron homeostasis. The iron-sensing mechanisms and the role of intracellular iron in modulating hepatic hepcidin secretion are unclear. Therefore, we created a novel cell line, recombinant-TfR1 HepG2, expressing iron-response-element-independent TFRC mRNA to promote cellular iron-overload and examined the effect of excess holotransferrin (5g/L) on cell-surface TfR1, iron content, hepcidin secretion and mRNA expressions of TFRC, HAMP, SLC40A1, HFE and TFR2. Results showed that the recombinant cells exceeded levels of cell-surface TfR1 in wild-type cells under basal (2.8-fold; p<0.03) and holotransferrin-supplemented conditions for 24h and 48h (4.4- and 7.5-fold, respectively; p<0.01). Also, these cells showed higher intracellular iron content than wild-type cells under basal (3-fold; p<0.03) and holotransferrin-supplemented conditions (6.6-fold at 4h; p<0.01). However, hepcidin secretion was not higher than wild-type cells. Moreover, holotransferrin treatment to recombinant cells did not elevate HAMP responses compared to untreated or wild-type cells. In conclusion, increased intracellular iron content in recombinant cells did not increase hepcidin responses compared to wild-type cells, resembling hemochromatosis. Furthermore, TFR2 expression altered within 4h of treatment, while HFE expression altered later at 24h and 48h, suggesting that TFR2 may function prior to HFE in HAMP regulation.

    AB - Hepcidin is the key regulator of systemic iron homeostasis. The iron-sensing mechanisms and the role of intracellular iron in modulating hepatic hepcidin secretion are unclear. Therefore, we created a novel cell line, recombinant-TfR1 HepG2, expressing iron-response-element-independent TFRC mRNA to promote cellular iron-overload and examined the effect of excess holotransferrin (5g/L) on cell-surface TfR1, iron content, hepcidin secretion and mRNA expressions of TFRC, HAMP, SLC40A1, HFE and TFR2. Results showed that the recombinant cells exceeded levels of cell-surface TfR1 in wild-type cells under basal (2.8-fold; p<0.03) and holotransferrin-supplemented conditions for 24h and 48h (4.4- and 7.5-fold, respectively; p<0.01). Also, these cells showed higher intracellular iron content than wild-type cells under basal (3-fold; p<0.03) and holotransferrin-supplemented conditions (6.6-fold at 4h; p<0.01). However, hepcidin secretion was not higher than wild-type cells. Moreover, holotransferrin treatment to recombinant cells did not elevate HAMP responses compared to untreated or wild-type cells. In conclusion, increased intracellular iron content in recombinant cells did not increase hepcidin responses compared to wild-type cells, resembling hemochromatosis. Furthermore, TFR2 expression altered within 4h of treatment, while HFE expression altered later at 24h and 48h, suggesting that TFR2 may function prior to HFE in HAMP regulation.

    KW - Hepcidin

    KW - Iron

    KW - HepG2

    KW - Hepatocyte

    KW - Transferrin

    U2 - 10.1016/j.bcmd.2016.06.008

    DO - 10.1016/j.bcmd.2016.06.008

    M3 - Article

    VL - 61

    SP - 37

    EP - 45

    JO - Blood Cells, Molecules, and Diseases

    JF - Blood Cells, Molecules, and Diseases

    SN - 1079-9796

    ER -